摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,3-bis(4-methoxyphenyl)-4,7-dihydro-2H-isoindole | 316124-40-0

中文名称
——
中文别名
——
英文名称
1,3-bis(4-methoxyphenyl)-4,7-dihydro-2H-isoindole
英文别名
——
1,3-bis(4-methoxyphenyl)-4,7-dihydro-2H-isoindole化学式
CAS
316124-40-0
化学式
C22H21NO2
mdl
——
分子量
331.414
InChiKey
HNRFCLCIOMFCBC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    25
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    34.2
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    1,3-bis(4-methoxyphenyl)-4,7-dihydro-2H-isoindole 在 10percent Pd/C ammonium formate 作用下, 以 乙醇 为溶剂, 生成 1,3-di-(4-methoxyphenyl)-4,5,6,7-tetrahydro-2H-isoindole
    参考文献:
    名称:
    1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole Derivatives:  A New Series of Potent and Selective COX-2 Inhibitors in Which a Sulfonyl Group Is Not a Structural Requisite
    摘要:
    Novel tetrahydro-2H-isoindoles have been prepared and evaluated as inhibitors of the COX-2 isoenzyme. A 1,S-diaryl substitution on the central polycyclic ring system and absence of a sulfonyl moiety are the two structural features of this chemical series. A short and easy synthetic pathway produced several derivatives which were shown to be potent and selective COX-2 vs COX-1 inhibitors (IC50 = 0.6-100 nM for COX-2, 100->1000 nM for COX-1). Structural modifications established that a bicyclic ring appended to the pyrrole nucleus and 4,4'-difluoro substitution on the phenyl rings were optimal for high inhibitory potency. Activity was confirmed in the human whole blood assay and subsequently in the murine air-pouch model in which in vivo PGE2 inhibitory activity was evaluated with respect to gastric tolerance (ED50 for inhibition of exudate PGE2 of 3 mg/kg and gastric PGEB of 20 mg/kg). Gastric tolerance was further assessed after administration to mice of high doses (up to 400 mg/kg) of the inhibitors by measurement of gastric damage. This panel of studies allowed selection of a number of tetrahydro-2H-isoindoles which were compared in the adjuvant-induced arthritis model. Compounds 32 and 37 showed the most potent activity with ED50 values for edema inhibition in the noninjected paw of 0.35 and 0.15 mg/kg/day, respectively, after oral administration. In addition, this interesting antiinflammatory profile was accompanied by a protective effect against arthritis-induced osteopenia, the decrease being 50% with a dose of 0.25 mg/kg/day.
    DOI:
    10.1021/jm990965x
  • 作为产物:
    参考文献:
    名称:
    1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole Derivatives:  A New Series of Potent and Selective COX-2 Inhibitors in Which a Sulfonyl Group Is Not a Structural Requisite
    摘要:
    Novel tetrahydro-2H-isoindoles have been prepared and evaluated as inhibitors of the COX-2 isoenzyme. A 1,S-diaryl substitution on the central polycyclic ring system and absence of a sulfonyl moiety are the two structural features of this chemical series. A short and easy synthetic pathway produced several derivatives which were shown to be potent and selective COX-2 vs COX-1 inhibitors (IC50 = 0.6-100 nM for COX-2, 100->1000 nM for COX-1). Structural modifications established that a bicyclic ring appended to the pyrrole nucleus and 4,4'-difluoro substitution on the phenyl rings were optimal for high inhibitory potency. Activity was confirmed in the human whole blood assay and subsequently in the murine air-pouch model in which in vivo PGE2 inhibitory activity was evaluated with respect to gastric tolerance (ED50 for inhibition of exudate PGE2 of 3 mg/kg and gastric PGEB of 20 mg/kg). Gastric tolerance was further assessed after administration to mice of high doses (up to 400 mg/kg) of the inhibitors by measurement of gastric damage. This panel of studies allowed selection of a number of tetrahydro-2H-isoindoles which were compared in the adjuvant-induced arthritis model. Compounds 32 and 37 showed the most potent activity with ED50 values for edema inhibition in the noninjected paw of 0.35 and 0.15 mg/kg/day, respectively, after oral administration. In addition, this interesting antiinflammatory profile was accompanied by a protective effect against arthritis-induced osteopenia, the decrease being 50% with a dose of 0.25 mg/kg/day.
    DOI:
    10.1021/jm990965x
点击查看最新优质反应信息

文献信息

  • Nouveaux derives de pyrrole leur procédé de preparation et les compositions pharmaceutiques qui les contiennent
    申请人:ADIR ET COMPAGNIE
    公开号:EP0921119A1
    公开(公告)日:1999-06-09
    Composés de formule (I) : dans laquelle : Rreprésente un atome d'hydrogène, un groupement alkyle, un groupement amino éventuellement substitué ou un groupement acyle (C1-C6) linéaire ou ramifié, R1, R2,identiques ou différents, représentent chacun indépendamment l'un de l'autre un groupement aryle, hétéroaryle ou cycloalkyle (C5-C7), chacun de ces groupements pouvant être éventuellement substitué, A,avec les atomes communs du pyrrole, représente un cycloalkyle (C3-C12), monocyclique ou bicyclique, saturé ou insaturé, un hétérocycle saturé de 5 à 7 chaînons contenant un ou deux atomes d'azote ou un oxa-7 bicyclo[2.2.1]heptane, chacun de ces cycles pouvant être éventuellement substitué, leurs isomères ainsi que leurs sels d'addition à un acide ou à une base pharmaceutiquement acceptable. Medicaments.
    式(I)化合物 其中: R 代表氢原子、烷基、任选取代的氨基或直链或支链(C1-C6)酰基、 R1 和 R2(可以相同或不同)各自独立地代表芳基、杂芳基或(C5-C7)环烷基,其中每个基团都有可能被任选取代、 A,连同吡咯的公共原子,代表饱和或不饱和、单环或双环(C3-C12)环烷基、含有一个或两个氮原子的饱和 5 至 7 元杂环或 7-氧杂双环[2.2.1]庚烷,其中每个环都可能被任选取代、 它们的异构体及其与药学上可接受的酸或碱的加成盐。 药物。
  • US6063804A
    申请人:——
    公开号:US6063804A
    公开(公告)日:2000-05-16
  • US6114360A
    申请人:——
    公开号:US6114360A
    公开(公告)日:2000-09-05
  • [EN] ENHANCED SELECTIVITY IN THE SYNTHESIS OF DTPA ESTERS FOM DIETHYLENETRIAMINE<br/>[FR] RENFORCEMENT DE LA SELECTIVITE DANS LA SYNTHESE D'ESTERS D'ACIDE DIETHYLENE TRIAMINEPENTA ACETIQUE (DPTA) A PARTIR DE DIETHYLENETRIAMINE
    申请人:MALLINCKRODT INC
    公开号:WO2000058267A1
    公开(公告)日:2000-10-05
    The synthesis of compounds of formula (XI) is disclosed. These compounds are useful intermediates in the synthesis of compounds of formula (X). These compounds are useful in the preparation of nuclear pharmaceuticals such as those used for tumor imaging or tumor therapy.
  • 1,3-Diaryl-4,5,6,7-tetrahydro-2<i>H</i>-isoindole Derivatives:  A New Series of Potent and Selective COX-2 Inhibitors in Which a Sulfonyl Group Is Not a Structural Requisite
    作者:Bernard Portevin、Charles Tordjman、Philippe Pastoureau、Jacqueline Bonnet、Guillaume De Nanteuil
    DOI:10.1021/jm990965x
    日期:2000.11.1
    Novel tetrahydro-2H-isoindoles have been prepared and evaluated as inhibitors of the COX-2 isoenzyme. A 1,S-diaryl substitution on the central polycyclic ring system and absence of a sulfonyl moiety are the two structural features of this chemical series. A short and easy synthetic pathway produced several derivatives which were shown to be potent and selective COX-2 vs COX-1 inhibitors (IC50 = 0.6-100 nM for COX-2, 100->1000 nM for COX-1). Structural modifications established that a bicyclic ring appended to the pyrrole nucleus and 4,4'-difluoro substitution on the phenyl rings were optimal for high inhibitory potency. Activity was confirmed in the human whole blood assay and subsequently in the murine air-pouch model in which in vivo PGE2 inhibitory activity was evaluated with respect to gastric tolerance (ED50 for inhibition of exudate PGE2 of 3 mg/kg and gastric PGEB of 20 mg/kg). Gastric tolerance was further assessed after administration to mice of high doses (up to 400 mg/kg) of the inhibitors by measurement of gastric damage. This panel of studies allowed selection of a number of tetrahydro-2H-isoindoles which were compared in the adjuvant-induced arthritis model. Compounds 32 and 37 showed the most potent activity with ED50 values for edema inhibition in the noninjected paw of 0.35 and 0.15 mg/kg/day, respectively, after oral administration. In addition, this interesting antiinflammatory profile was accompanied by a protective effect against arthritis-induced osteopenia, the decrease being 50% with a dose of 0.25 mg/kg/day.
查看更多